Literature DB >> 25630429

Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer.

Nadia Haj Mohammad1, Martijn Kamphuis2, Maarten C C M Hulshof2, Lotte J Lutkenhaus2, Suzanne S Gisbertz3, Jacques J G H M Bergman4, H A C M Rianne de Bruin-Bon5, Elisabeth D Geijsen2, Arjan Bel2, S Mathijs Boekholdt5, Hanneke W M van Laarhoven6.   

Abstract

BACKGROUND AND
PURPOSE: Neoadjuvant chemoradiation (nCRT) followed by surgery is considered curative intent treatment for patients with resectable esophageal cancer. The aim was to establish hemodynamic aspects of changes in heart volume and to explore whether changes in heart volume resulted in clinically relevant changes in the dose distribution of radiotherapy.
METHODS: A prospective study was conducted in patients who were treated with nCRT consisting of carboplatin and paclitaxel concomitant with radiotherapy (41.4 Gy/1.8 Gy per fraction). Physical parameters, cardiac volume on CT and Cone beam CT, cardiac blood markers and cardiac ultrasound were obtained.
RESULTS: In 23 patients a significant decrease of 55.3 ml in heart volume was detected (95% CI 36.7-73.8 ml, p<0.001). There was a decrease in both systolic (mean decrease 18 mmHg, 95% CI 11-26 mmHg, p<0.001) and diastolic blood pressure (mean decrease 8 mmHg, 95% CI 2-14 mmHg, p=0.008) and an increase in heart rate with 6 beats/min (95% CI 1-11 beats/min, p=0.021). Except for Troponin T, no change in other cardiac markers and echocardiography parameters were observed. The change in heart volume did not result in a clinically relevant change in radiation dose distribution.
CONCLUSION: Heart volume was significantly reduced, but was not accompanied by overt cardiac dysfunction. All observed changes in hemodynamic parameters are consistent with volume depletion. Adaptation of the treatment plan during the course of radiotherapy is not advocated.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac volume; Esophageal cancer; Neoadjuvant chemoradiation

Mesh:

Substances:

Year:  2015        PMID: 25630429     DOI: 10.1016/j.radonc.2014.12.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

Authors:  Gilles Créhange; Thierry Conroy
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

2.  Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.

Authors:  Charlotte I Stroes; Sandor Schokker; Aafke Creemers; Remco J Molenaar; Maarten C C M Hulshof; Stephanie O van der Woude; Roel J Bennink; Ron A A Mathôt; Kausilia K Krishnadath; Cornelis J A Punt; Rob H A Verhoeven; Martijn G H van Oijen; Geert-Jan Creemers; Grard A P Nieuwenhuijzen; Maurice J C van der Sangen; Laurens V Beerepoot; Joos Heisterkamp; Maartje Los; Marije Slingerland; Annemieke Cats; Geke A P Hospers; Maarten F Bijlsma; Mark I van Berge Henegouwen; Sybren L Meijer; Hanneke W M van Laarhoven
Journal:  J Clin Oncol       Date:  2019-12-06       Impact factor: 44.544

3.  Lung and Heart Dose Variability During Radiation Therapy of Non-Small Cell Lung Cancer.

Authors:  Nuzhat Jan; Christopher Guy; Leonid B Reshko; Geoffrey D Hugo; Elisabeth Weiss
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-08       Impact factor: 7.038

4.  Higher pre-treatment skin sympathetic nerve activity and elevated resting heart rate after chemoradiotherapy predict worse esophageal cancer outcomes.

Authors:  Chen-Ling Tang; Wei-Chung Tsai; Jui-Ying Lee; Yao-Kuang Wang; Yi-Hsun Chen; Yu-Wei Liu; Ming-Chieh Lin; Pen-Tzu Fang; Yu-Ling Huang; I-Chen Wu
Journal:  BMC Cancer       Date:  2022-10-22       Impact factor: 4.638

5.  The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer.

Authors:  Emmanouil V Dermitzakis; Vasilios K Kimiskidis; George Lazaridis; Zoi Alexopoulou; Eleni Timotheadou; Alexandros Papanikolaou; Ourania Romanidou; George Georgiadis; Konstantine T Kalogeras; Iakovos Tsiptsios; Basil Tarlatzis; George Fountzilas
Journal:  BMC Neurol       Date:  2016-10-01       Impact factor: 2.474

6.  Intrafractional dose variation and beam configuration in carbon ion radiotherapy for esophageal cancer.

Authors:  M F Haefner; F Sterzing; D Krug; S A Koerber; O Jaekel; J Debus; M M Haertig
Journal:  Radiat Oncol       Date:  2016-11-15       Impact factor: 3.481

7.  Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database.

Authors:  Laila Gharzai; Vivek Verma; Kyle A Denniston; Abhijeet R Bhirud; Nathan R Bennion; Chi Lin
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

8.  Changes in cardiac volume determined with repeated enhanced 4DCT during chemoradiotherapy for esophageal cancer.

Authors:  Xue Wang; Jin-Zhi Wang; Jian-Bin Li; Ying-Jie Zhang; Feng-Xiang Li; Wei Wang; Yan-Luan Guo; Qian Shao; Min Xu; Xi-Jun Liu; Yue Wang
Journal:  Radiat Oncol       Date:  2018-09-18       Impact factor: 3.481

9.  Cone-Beam CT-based position verification for oesophageal cancer: Evaluation of registration methods and anatomical changes during radiotherapy.

Authors:  A van Nunen; M J C van der Sangen; M van Boxtel; P M A van Haaren
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2017-09-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.